Experienced in Lung Metastases

Fernanda G. Herrera

Lausanne Branch, 
Lausanne, VD, CH 
Experienced in Lung Metastases
Lausanne Branch, 
Lausanne, VD, CH 
OverviewLocationsClinical Research

Overview

Fernanda Herrera practices in Lausanne, Switzerland. Ms. Herrera is rated as an Experienced expert by MediFind in the treatment of Lung Metastases. Her top areas of expertise are Prostate Cancer, Cervical Cancer, Ovarian Cancer, Hysterectomy, and Salpingo-Oophorectomy.

Her clinical research consists of co-authoring 79 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Lung Metastases.

Gender
Female

Locations

Lausanne Branch, Lausanne, VD, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer
A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
RACIN, A Phase I Study of the Combination of Nivolumab Associated With Low-dose Radiation, Aspirin/ Celecoxib, and Either Ipilimumab or Low-dose Cyclophosphamide, Followed by Nivolumab Maintenance, in Patients With Advanced, TIL-negative Solid Tumors
RACIN, A Phase I Study of the Combination of Nivolumab Associated With Low-dose Radiation, Aspirin/ Celecoxib, and Either Ipilimumab or Low-dose Cyclophosphamide, Followed by Nivolumab Maintenance, in Patients With Advanced, TIL-negative Solid Tumors
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Combination product
Study Phase: Phase 1
View 1 Less Clinical Trial

79 Total Publications

Correction: Cloître et al. Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study. Cancers 2024, 16, 2097.
Correction: Cloître et al. Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study. Cancers 2024, 16, 2097.
Journal: Cancers
Published: July 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Herrera's expertise for a condition
ConditionClose
        View All 14 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile